Skip to main content

Table 3 Univariate Fisher’s exact test analysis for pathological complete response according to clinicopathological and molecular features

From: Claudin-low breast cancers: clinical, pathological, molecular and prognostic characterization

A. Clinicopathological features

Claudin-low

All samples

N

RD

pCR

p-value*

OR [95CI]

N

RD

pCR

p-value*

OR [95CI]

Age at diagnosis, years

   

0.392

0.76

   

0.09

0.8

≤50

123

80 (52%)

43 (59%)

 

[0.41-1.37]

697

521 (53%)

176 (58%)

 

[0.61-1.04]

>50

104

74 (48%)

30 (41%)

  

595

469 (47%)

126 (42%)

  

Pathological tumor size

   

1.00

0.93

   

0.859

1.1

pT1

5

3 (8%)

2 (9%)

 

[0.1-11.96]

44

32 (14%)

12 (13%)

 

[0.53-2.53]

pT2-3

55

34 (92%)

21 (91%)

  

279

196 (86%)

83 (87%)

  

Histological grade

   

0.06

Inf

   

1.68E-04

8.1

1

8

8 (6%)

0 (0%)

 

[0.82-Inf]

53

51 (6%)

2 (1%)

 

[2.11-69.38]

2-3

204

136 (94%)

68 (100%)

  

1126

854 (94%)

272 (99%)

  

Histological type

   

0.125

    

0.75

 

IDC

77

45 (67%)

32 (84%)

  

468

337 (82%)

131 (85%)

  

ILC

5

3 (4%)

2 (5%)

  

15

10 (2%)

5 (3%)

  

MIX

6

6 (9%)

0 (0%)

  

37

29 (7%)

8 (5%)

  

other

17

13 (19%)

4 (11%)

  

47

36 (9%)

11 (7%)

  

ESR1 expression status

   

0.07

0.47

   

7.21E-18

0.3

negative

183

119 (77%)

64 (88%)

 

[0.19-1.07]

697

470 (47%)

227 (75%)

 

[0.22-0.4]

positive

45

36 (23%)

9 (12%)

  

597

522 (53%)

75 (25%)

  

PGR expression status

   

0.42

0.64

   

4.24E-08

0.38

negative

195

130 (84%)

65 (89%)

 

[0.24-1.57]

979

716 (72%)

263 (87%)

 

[0.26-0.56]

positive

33

25 (16%)

8 (11%)

  

315

276 (28%)

39 (13%)

  

ERBB2 expression status

   

0.472

1.7

   

5.90E-04

1.9

negative

219

150 (97%)

69 (95%)

 

[0.33-8.34]

1125

881 (89%)

244 (81%)

 

[1.31-2.7]

positive

9

5 (3%)

4 (5%)

  

169

111 (11%)

58 (19%)

  

Triple-negative expression status

   

0.285

1.4

   

8.16E-10

2.3

no

71

52 (34%)

19 (26%)

 

[0.74-2.83]

777

642 (65%)

135 (45%)

 

[1.73-2.97]

yes

157

103 (66%)

54 (74%)

  

517

350 (35%)

167 (55%)

  

DLDA30 [18]

   

1.61E-02

0.49

   

7.53E-23

0.26

pCR-like

120

73 (47%)

47 (64%)

 

[0.27-0.91]

439

264 (27%)

175 (58%)

 

[0.2-0.35]

RD-like

108

82 (53%)

26 (36%)

  

855

728 (73%)

127 (42%)

  

Stromal metagene [51]

   

0.623

1.2

   

0.12

0.81

pCR-like

55

39 (25%)

16 (22%)

 

[0.59-2.5]

642

480 (48%)

162 (54%)

 

[0.62-1.06]

RD-like

173

116 (75%)

57 (78%)

  

652

512 (52%)

140 (46%)

  

A-score [21]

   

3.15E-03

3.9

   

1.48E-04

2

RD-like

37

31 (32%)

6 (11%)

 

[1.46-12.32]

258

196 (46%)

62 (30%)

 

[1.36-2.85]

pCR_Like

118

67 (68%)

51 (89%)

  

378

233 (54%)

145 (70%)

  

RB-loss signature [52]

   

1.00

0.96

   

6.52-03

1.7

Low (RD-like)

212

144 (93%)

68 (93%)

 

[0.25-3.15]

1150

895 (90%)

255 (84%)

 

[1.14-2.51]

High (pCR-like)

16

11 (7%)

5 (7%)

  

144

97 (10%)

47 (16%)

  
  1. *, Fisher’s exact test.
  2. IDC: invasive ductal carcinoma; ILC: invasise lobular carcinoma; MIX: mixed; pCR: pathological complete response; RD: residual disease; OR: odds ratio; 95CI: 95% confidence interval.
  3. P-values < 0.05 are represented in boldface.